Dermatology
News, opinions and meeting coverage in dermatology.
— Our panel of experts discuss how they monitor patients on biologics and JAK inhibitors
Latest in Dermatology
Meta-analysis suggests lower risk of suicide attempts years after starting isotretinoin
Roundtable of experts weigh in on "unprecedented" efficacy, and safety issues
FDA should consider warning labels based on study results, researchers argue
Prescribing information changed for levetiracetam, clobazam
FDA should consider warning labels based on study results, researchers argue
Prescribing information changed for levetiracetam, clobazam
Dermatology Case Studies
Treatment-resistant juvenile dermatomyositis resolved by targeting elevated interferon-beta
Incision sites were itchy, painful, red, and oozing and were not showing signs of healing
Clinicians consider a number of differential diagnoses before making the call
More in Dermatology
A 51-year-old man visited his doctor concerned about an asymptomatic rash that developed over his face within the last month. Can you diagnose the patient?
With greater exposure on social media, more youths are trying cosmetic treatments
Our panel of experts discuss the appropriate time to introduce systemic therapy or switch agents
Treatment-resistant juvenile dermatomyositis resolved by targeting elevated interferon-beta
Favorable results with TAK-279 and deucravacitinib in studies at ACR
We've got great treatments, says Steven Feldman, the key is getting patients to use them
Our panel of experts discuss the "explosion" in new systemic and topical agents
James Del Rosso, DO, says to keep an open mind when determining the best option for patients
A 42-year-old woman presented to the ED noting that she felt a stinging sensation on her arm while she was cleaning and organizing her basement, the previous day. Can you diagnose the patient?
Seladelpar also improved markers of disease activity versus placebo
Off-label use along with antihistamines improved activity, itch, and wheal count scores
Remibrutinib demonstrated superiority over placebo in both the REMIX-1 and -2 trials
More phase II data build case for izokibep
Pause on ACE inhibitors, ARBs yields more acute hypertension with no prevention of hypotension
